Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IN8BIO, INC.INAB · Entity 7941 | Director | May 09, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IN8BIO, INC.
Report date May 09, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-05-09 | Direct | 22,000 |
Reported balance
After 2026-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-09 · Grant · Acquired 22,000 · Balance 22,000 F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AVEO PHARMACEUTICALS, INC.
Report date January 19, 2023 · Filed January 19, 2023
Section 16 reporting ended · disclosed 2023-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.31 · Expires 2031-01-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2031-01-05 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-19 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2023-01-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-19 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2026 Filed May 12, 2026 20:30 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001839156-26-000002 · form4-05122026_040508.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-09 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 63,150 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001415889-25-012651 · form4-05122025_040512.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,150 Underlying: Common Stock · 63,150 shares Expires 2035-05-08 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 27, 2025 Filed May 8, 2025 00:45 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 81,967 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-012291 · form4-05072025_080511.xml · derivative · entry 2 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,967 Underlying: Common Stock · 81,967 shares Expires 2028-12-13 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 8, 2025 00:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Disposition to issuerSeries B Warrants (right to buy) · Derivative | 81,967 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-012291 · form4-05072025_080511.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81,967 shares Expires 2028-12-13 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F3 · price: The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 37,655 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-030066 · form4-12232024_041222.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,655 Underlying: Common Stock · 37,655 shares Expires 2034-12-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 21:00 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 33,650 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016966 · form4-06142024_050607.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,650 Underlying: Common Stock · 33,650 shares Expires 2034-06-12 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:54 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001415889-24-003025 · form4-02082024_090213.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-02-07 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on March 7, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:26 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 81,967 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001209191-23-058720 · doc4.xml · derivative · entry 3 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,967 Underlying: Common Stock · 81,967 shares Expires 2028-12-13 F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:26 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries A Warrants (right to buy) · Derivative | 81,967 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-058720 · doc4.xml · derivative · entry 2 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,967 Underlying: Common Stock · 81,967 shares Expires 2025-06-13 F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:26 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantCommon Stock | 81,967 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-058720 · doc4.xml · nonDerivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,967 F1 · price: The reported securities are included within 81,967 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 21:26 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 54,800 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001209191-23-057915 · doc4.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,800 Underlying: Common Stock · 54,800 shares Expires 2033-12-06 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on January 6, 2024, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:15 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,500 | Not disclosed Strike: $4.27 | Not disclosed |
DisclosureSEC source: 0000899243-23-002190 · doc4.xml · derivative · entry 3 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2032-06-06 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:15 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $6.46 | Not disclosed |
DisclosureSEC source: 0000899243-23-002190 · doc4.xml · derivative · entry 2 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-01-05 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| January 19, 2023 Filed Jan 19, 2023 17:15 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $6.31 | Not disclosed |
DisclosureSEC source: 0000899243-23-002190 · doc4.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F1 · price: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. F1 · derivative.exercise_date: This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 16:58 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001628280-22-016603 · wf-form4_165472189665790.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-06-06 F1 · derivative.exercise_date: The shares underlying this option vest in twelve equal monthly installments beginning July 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| April 13, 2021 Filed Apr 14, 2021 18:21 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000899243-21-015831 · doc4.xml · derivative · entry 2 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-05 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 1, 2021 through January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 19:01 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.31 | $0.00 |
DisclosureSEC source: 0000899243-21-001226 · doc4.xml · derivative · entry 1 Epperly Corinne · CIK 0001839156 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 1, 2021 through January 1, 2024, subject to the Reporting Person's continued service to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.